An alcohol-in-oil microcapsule bead, a method for preparing the same using microfluidic technology, and use thereof

Abstract

The application belongs to the technical field of skin care product preparation, and discloses an alcohol-in-oil microcapsule bead and a method for preparing the same by using microfluidic technology and application of the same. The alcohol-in-oil microcapsule bead comprises a shell and a core material, the shell is formed by solidification of an oil phase solution, and the core material is composed of an alcohol phase solution; the oil phase solution is composed of an oil phase film material, an oil phase solvent and an oil phase active substance, the oil phase film material is composed of HDI / trimethylol hexyl lactone cross-linked polymer and castor oil / IPDI copolymer, the oil phase solvent is composed of squalane, white pool flower seed oil and diisostearyl malate, and the oil phase active substance is composed of ascorbic acid tetraisopalmitate, tocopherol and ceramide NP; the alcohol phase solution is composed of an alcohol phase solvent and an alcohol phase active substance, the alcohol phase solvent is butanediol, and the alcohol phase active substance is Ampelopsis aconitifolia extract.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of skin care product preparation, and particularly relates to an alcohol-in-oil microcapsule bead and a method for preparing the same by using microfluidic technology and purposes thereof. BACKGROUND

[0002] At present, microencapsulation technology and drop forming technology are widely used in the technical field of cosmetic preparation. Such technology can wrap sensitive ingredients to isolate air, light and temperature damage, reduce skin irritation, mask bad color or odor, and even control the release speed of active ingredients and extend the action time. The products prepared by such technology include drop pills, burst beads, microcapsule oil beads and wax beads.

[0003] Drop pills are obtained by cross-linking reaction of algal extract such as sodium alginate and divalent metal ions using gel hardening principle. The carboxyl group on the molecular chain of sodium alginate combines with calcium ions to form a three-dimensional network structure of gel, which wraps the active ingredients, nutrients and other substances in cosmetics, thereby forming an algal bead. By controlling the reaction conditions such as sodium alginate concentration, calcium ion concentration, reaction temperature and time, the size, shape and mechanical properties of the algal bead can be adjusted.

[0004] Burst beads are obtained by forming an emulsion of oily ingredients and aqueous ingredients in cosmetics by emulsification technology, and the oil droplets or water beads in the emulsion are the inner core of the burst beads. Then, a layer of solid film is formed on the surface of the emulsion droplets by using high molecular film-forming materials (such as gelatin, chitosan, etc.), which wraps the inner core to form burst beads. When external force acts on the burst beads, the film breaks and the internal oily or aqueous ingredients are released. In the preparation process, the emulsification conditions such as the type and amount of emulsifier, oil-water ratio, stirring speed and time need to be accurately controlled to obtain stable emulsion and uniform burst bead particle size.

[0005] Microcapsule oil beads are prepared by using a gel hardener to play a gelation role, wrapping part of the emollient and a small amount of active functional material, colorant inside. By controlling the temperature, the mixture is dissolved uniformly under high temperature conditions, and the stirring speed is controlled to control the shape and size, and then the uniform oil paste is formed by cooling. In the preparation process, the temperature conditions need to be accurately controlled to obtain a stable shape, uniform softness and microcapsule oil bead particle size.

[0006] Wax beads are prepared by dissolving and mixing the forming agent (wax oil) uniformly at high temperature, then adding the base oil uniformly, then adding the emulsifier uniformly, controlling the temperature to a certain temperature range, then adding the active functional ingredients, forming a uniform and stable emulsion mixture, and then using drop pill equipment to prepare the wax beads for cosmetics.

[0007] The above existing technologies have the following disadvantages:

[0008] (1) As hydrophilic microbeads, drop pills have functional limitations and can only encapsulate some types of water-soluble active ingredients. The stability of drop pills is limited, and changes in temperature and pH value can cause significant differences in the morphology of microbeads, breakage of the capsule wall, and leakage of the components, affecting the stability and efficacy of other cosmetics. The production quality of drop pills is also limited, with a wide particle size distribution. It is difficult to completely control the uniformity of particle size through production equipment, and the mechanical strength of microbeads is low, making them prone to breakage during production, storage, and use due to external forces such as stirring and extrusion. In addition, the quality of algal raw materials is affected by factors such as growing environment and seasonal climate, which can also lead to quality differences between batches of microbeads, ultimately affecting the stability of product quality.

[0009] (2) Bursting beads use high-molecular material film wrapping technology, which dissolves in water. When bursting beads come into contact with water, they may break due to changes in water pressure and surface tension, releasing the components inside. If the quality of bursting beads is poor or they are not stored properly, they may not break completely or release components uniformly when they come into contact with water. The production cost of bursting beads is high, and the preparation process is extremely complex, leading to an increase in cost and affecting the market competitiveness of the product to some extent. Bursting beads also have stability problems. During storage, they are easily affected by temperature and humidity, leading to breakage and leakage of the contents, affecting the stability and shelf life of the product. The effectiveness and experience of using bursting beads are difficult to control. Bursting beads need to be broken by external factors such as pressing and rubbing. If the force is not controlled properly, various problems may occur, such as incomplete breakage. This ultimately leads to inconsistent release of components each time the product is used, affecting the effectiveness and experience of use.

[0010] (3) The compatibility of microcapsule oil beads is limited, and the active ingredients that can be encapsulated are also limited, which restricts the product formula and can only encapsulate oil-soluble active ingredients, but not water-soluble or alcohol-soluble active ingredients. The stability of microcapsule oil beads is difficult to control, and the capsule wall may be affected by environmental factors such as high temperature, high humidity, or specific chemicals, leading to breakage of the capsule wall and leakage of the oil inside, affecting the quality and stability of the product. Microcapsule oil beads are prone to oxidation, which can cause the oil beads to deteriorate. If natural pigments are used as colorants for oil beads, oxidation of natural pigments can cause significant differences in the overall appearance of the color, affecting the quality of the product. During the production and preparation process of microcapsule oil beads, it is difficult to accurately control the particle size of the microcapsule oil beads, leading to uneven particle size distribution. This can cause differences in appearance, texture, and performance, affecting the effectiveness and consistency of the product. If the oil beads encapsulate functional ingredients, the release process may be difficult to control accurately, which can affect the timely and effective use of the functional ingredients, affecting the skin care or absorption effect of the cosmetic.

[0011] (4) Wax beads are not easy to clean, and the wax has certain hydrophobicity and is not easy to clean with water. Special makeup remover products are needed to thoroughly clean it, otherwise the residual wax beads may cause damage to the skin. The poor air permeability of the wax beads may affect the respiration of the skin, hinder the normal metabolism of the skin, and long-term use may cause skin problems such as clogged pores, acne, etc. If the particles of the wax beads are small, they may enter the pores, especially for people with oily skin or large pores, which is more likely to cause clogged pores and cause skin inflammation. The wax beads lack functionality. Ordinary wax beads are usually just simple oil particles and do not have special functional properties. In some fields that have specific functional requirements for products, such as drug delivery and biosensors, ordinary oil beads may not meet the needs and need to be modified or added with functional ingredients to function. The biodegradability of the wax beads is limited. Some oils used in the oil beads may have poor biodegradability and are difficult to decompose naturally in the environment, which may cause some pollution to the environment. SUMMARY

[0012] In order to overcome the shortcomings and deficiencies existing in the prior art, the primary purpose of the present application is to provide an alcohol-in-oil microcapsule bead.

[0013] Another purpose of the present application is to provide a method for preparing the above-mentioned alcohol-in-oil microcapsule bead using microfluidic technology.

[0014] Still another purpose of the present application is to provide an application of the above-mentioned alcohol-in-oil microcapsule bead.

[0015] The purposes of the present application are achieved by the following technical solutions:

[0016] An alcohol-in-oil microcapsule bead, which comprises an outer shell and an inner core material, the outer shell is formed by solidifying an oil phase solution, and the inner core material is composed of an alcohol phase solution;

[0017] The oil phase solution is composed of an oil phase film material, an oil phase solvent and an oil phase active substance, the oil phase film material is composed of HDI / trimethylol hexyl lactone cross-linked polymer and castor oil / IPDI copolymer, the oil phase solvent is composed of squalane, white pool flower seed oil and diisostearyl malate, and the oil phase active substance is composed of ascorbic acid tetraisopalmitate, tocopherol and ceramide NP;

[0018] The alcohol phase solution is composed of an alcohol phase solvent and an alcohol phase active substance, the alcohol phase solvent is butanediol, and the alcohol phase active substance is an extract of AMPELOPSIS GROSSEDENTATA.

[0019] The oil phase solution is composed of the following components by mass percentage: HDI / trimethylol hexyl lactone cross-linked polymer 4.8~10%, castor oil / IPDI copolymer 14~22%, squalane 40~50%, white pool flower seed oil 10~20%, diisostearyl malate 10~12%, ascorbic acid tetraisopalmitate 0.1~0.5%, tocopherol 1~5%, and ceramide NP 0.1~0.5%.

[0020] The alcohol phase solution is composed of the following components by mass percentage: Ampelopsis aconitifolia extract 20~40% and butanediol 60~80%.

[0021] The above-mentioned preparation method of the alcohol-in-oil microcapsule beads is according to the following operation steps:

[0022] (1) selecting an oil phase solution, an alcohol phase solution, and a continuous phase solution: the oil phase solution is composed of HDI / trimethylol hexyl lactone cross-linked polymer, castor oil / IPDI copolymer, squalane, white pool flower seed oil, diisostearyl malate, ascorbic acid tetraisopalmitate, tocopherol, and ceramide NP; the alcohol phase solution is composed of Ampelopsis aconitifolia extract and butanediol; and the continuous phase solution is composed of a stabilizer and pure water;

[0023] (2) selecting a flow focusing type microfluidic chip to prepare alcohol-in-oil microcapsule beads: the alcohol phase solution is injected from one end of the main channel close to the oil phase channel, and then the oil phase solution is injected from both ends of the oil phase channel; at the intersection of the oil phase channel and the main channel, the alcohol phase solution is squeezed and dispersed into droplets by the oil phase solution on both sides, and the oil phase solution containing the droplets continues to flow forward; the continuous phase solution is injected from both ends of the outer phase channel, and the oil phase solution containing the droplets is mixed with the continuous phase solution to form a suspension of alcohol-in-oil microcapsule beads, which flows out from the outlet of the main channel together, is cooled and cooled, is left to further solidify, and a stable suspension of alcohol-in-oil microcapsule beads is obtained.

[0024] The flow focusing type microfluidic chip in step (2) is provided with a main channel, an oil phase channel, and an outer phase channel, wherein the oil phase channel and the outer phase channel are sequentially arranged along the conveying direction of the main channel, the extension directions of the oil phase channel and the outer phase channel are perpendicular to the extension direction of the main channel, and the oil phase channel and the outer phase channel are respectively communicated with the main channel.

[0025] The continuous phase solution in step (1) is composed of the following components by mass percentage: stabilizer 0.1~0.5% and pure water 99.5~99.9%; and the stabilizer is carbomer or xanthan gum.

[0026] The mass percentages of the oil phase solution, the alcohol phase solution, and the continuous phase solution in step (1) are 40%, 20%, and 40%, respectively.

[0027] The flow rate ratio of the alcohol phase solution and the oil phase solution in step (2) is controlled at 1:4-1:8 to ensure that the particle size of the alcohol-in-oil microcapsule beads is controlled in the range of 0.5-1 mm.

[0028] The stable suspension product of the alcohol-in-oil microcapsule beads obtained in step (2) is further post-processed, including filtration and drying.

[0029] The use of the above-mentioned alcohol-in-oil microcapsule beads in the preparation of cosmetics with antioxidant, anti-glycation and anti-aging effects.

[0030] The present application has the following advantages and effects relative to the prior art:

[0031] (1) The traditional preparation method is difficult to accurately control the particle size and shape of the microcapsule beads, and the present application uses microfluidic technology to accurately control the fluid flow and parameters in the microchannel, which can realize accurate control of the particle size and shape of the alcohol-in-oil microcapsule beads, obtain highly uniform microcapsule beads, optimize the production technology, improve the production quality, reduce resource waste, and has the advantages of high efficiency and environmental protection.

[0032] (2) The product formula of the present application is comprehensively improved, the active ingredient is wrapped in multiple types, the shell can wrap gel hardener, emollient oil and oil-soluble active ingredient, and can also wrap colorant, and the core can wrap alcohol-soluble active ingredient.

[0033] (3) The preparation method of the present application effectively improves the encapsulation efficiency of alcohol active substances, accurately controls the mixing ratio and process of the oil phase and the alcohol phase by using microfluidic technology, and the alcohol phase can be uniformly and stably wrapped by the oil phase, reducing the loss of alcohol active substances in the preparation process, so that more alcohol can be effectively encapsulated in the microcapsule beads, and the alcohol can better play its role.

[0034] (4) The preparation method of the present application can significantly improve the stability of the active substance. The aqueous solution of Ampelopsis aconitifolia extract is easily affected by factors such as light, temperature and pH value, and is prone to degradation or deterioration, resulting in reduced activity and affecting the exertion of its efficacy; the microcapsule beads obtained by the method of the present application have the structure of oil wrapping alcohol-soluble active substances, and the oil phase acts as a barrier to effectively prevent the alcohol-soluble active ingredient Ampelopsis aconitifolia extract inside from directly contacting with the external environment, reduce the deterioration caused by oxidation, hydrolysis and other factors, and reduce the damage of these factors to Ampelopsis aconitifolia extract, thereby maintaining the stability of the active substance.

[0035] (5) The preparation method of the present application functionalizes the alcohol-in-oil microcapsule beads, according to the specific alcohol-soluble active substance wrapped by the core, the structure advantages of the microcapsule beads are exerted, flexible adjustment and reasonable use are made, so that the human skin can maximize the absorption and utilization value of the active substance.

[0036] (6) The structure of the oil-in-alcohol microcapsules of this invention facilitates better penetration of active ingredients into the skin; the oil phase can interact with the oils on the skin surface, increasing the affinity between the microcapsules and the skin, and carrying the *Ampelopsis grossedentata* extract to the deeper layers of the skin during penetration. The special structure of the oil-in-alcohol microcapsules of this invention helps to open the gaps in the stratum corneum, making it easier for the extract to penetrate the stratum corneum barrier, thereby improving the absorption rate of active ingredients, increasing their bioavailability, and better exerting their skincare effects, thus enhancing the whitening, antioxidant, and other effects of the product.

[0037] (7) The oil-in-alcohol microcapsules of this invention can reduce irritation, improve skin feel, and reduce irritation. For some people with sensitive skin, direct use of Ampelopsis lanceolata extract may cause skin discomfort. However, this invention encapsulates Ampelopsis lanceolata extract in microcapsules, isolating it from the skin in the initial stage of use, reducing its direct irritation to the skin, and also slowing down its release rate and reducing the local concentration, thereby reducing irritation. This invention combines Ampelopsis lanceolata extract and butylene glycol to form an alcohol phase substance, which can play a certain soothing role, making the product gentler to use and reducing the risk of allergies.

[0038] (8) The oil-in-alcohol microcapsule beads of the present invention have the characteristics of targeted delivery and slow release; by adjusting the formulation and structure of the microcapsule beads of the present invention, targeted delivery to specific skin layers or cells can be achieved, as well as slow release of alcohol-soluble active ingredients, prolonging their action time on the skin surface, so that the efficacy can be sustained.

[0039] (9) The method of preparing oil-in-alcohol microcapsules using microfluidic technology is suitable for continuous production. By adjusting the flow rate of the injected solution, large-scale preparation of oil-in-alcohol microcapsules can be achieved, thereby improving production efficiency and reducing production costs. Attached Figure Description

[0040] Figure 1 This is a schematic diagram of a flow-focusing microfluidic chip structure, where 1 is the main channel, 2 is the oil phase channel, 3 is the external phase channel, 4 is the alcohol phase solution, 5 is the oil phase solution, and 6 is the continuous phase solution.

[0041] Figure 2 This is a line graph showing the trend of DPPH clearance rate changes in the serum.

[0042] Figure 3 This is a line graph showing the trend of DPPH clearance rate in the positive control group.

[0043] Figure 4 The results and reference line graph show the scavenging effect of 1,3-diaminoguanidine hydrochloride on late glycosylation.

[0044] Figure 5is the result of advanced glycation end product clearance rate of different concentrations of serum and reference line graph.

[0045] Figure 6 is the result of cell toxicity of serum at different concentrations and reference line graph.

[0046] Figure 7 is the relative expression of DNMT1 gene line graph. DETAILED DESCRIPTION

[0047] The present application will be further described below in conjunction with specific examples and drawings, but should not be understood as limiting the present application. Example 1

[0048] A preparation method of alcohol-in-oil microcapsule beads, specifically according to the following operation steps:

[0049] (1) Selecting oil phase solution, alcohol phase solution and continuous phase solution: the oil phase solution is composed of HDI / trimethylol hexyl lactone cross-linked polymer, castor oil / IPDI copolymer, squalane, white pool rapeseed oil, diisostearyl malate, ascorbic acid tetraisopalmitate, tocopherol and ceramide NP; the alcohol phase solution is composed of Ampelopsis megalophylla extract and butanediol; the continuous phase solution is composed of stabilizer carbomer and pure water; the mass percentages of the oil phase solution, the alcohol phase solution and the continuous phase solution are 40%, 20% and 40% respectively;

[0050] (2) Preparing alcohol-in-oil microcapsule beads by using a flow focusing type microfluidic chip (structure diagram as shown in Figure 1 The flow focusing type microfluidic chip is provided with a main channel 1, an oil phase channel 2 and an external phase channel 3, wherein the oil phase channel 2 and the external phase channel 3 are sequentially arranged along the conveying direction of the main channel 1, the extension directions of the oil phase channel 2 and the external phase channel 3 are perpendicular to the extension direction of the main channel 1, and the oil phase channel 2 and the external phase channel 3 are respectively communicated with the main channel 1): the alcohol phase solution is injected from one end of the main channel close to the oil phase channel, and then the oil phase solution is injected from both ends of the oil phase channel, the flow rate ratio of the alcohol phase solution and the oil phase solution is controlled to be 1:4 to ensure that the particle size range of the obtained alcohol-in-oil microcapsule beads is controlled within 0.5-1mm; at the intersection of the oil phase channel and the main channel, the alcohol phase solution is extruded and dispersed into droplets by the oil phase solution on both sides, the oil phase solution containing the droplets continues to flow forward, the continuous phase solution is injected from both ends of the external phase channel, and the oil phase solution containing the droplets is mixed with the continuous phase solution to form a suspension of alcohol-in-oil microcapsule beads, which flows out from the outlet of the main channel together, and is cooled and cooled, and is further solidified to obtain a stable suspension product of alcohol-in-oil microcapsule beads.

[0051] Subsequent performance testing experiments, as needed, can be performed on the resulting stable suspension of alcohol-in-oil microcapsule beads before use, by filtering and drying the stable suspension of alcohol-in-oil microcapsule beads to obtain dried alcohol-in-oil microcapsule beads.

[0052] The raw material ratios (in mass percentage) for preparing the suspensions of alcohol-in-oil microcapsule beads of Examples 1-3 are shown in Table 1:

[0053] Table 1 Raw material ratios for preparing alcohol-in-oil microcapsule beads of Examples 1-3

[0054]

[0055] Example 1 is a suspension of alcohol-in-oil microcapsule beads 1 prepared according to the above preparation method and the raw material ratios shown in Table 1;

[0056] Example 2 is a suspension of alcohol-in-oil microcapsule beads 2 prepared according to the above preparation method and the raw material ratios shown in Table 1;

[0057] Example 3 is a suspension of multi-alcohol-in-oil microcapsule beads 3 prepared according to the above preparation method and the raw material ratios shown in Table 1;

[0058] Comparative Example 1 is a suspension of alcohol-in-oil microcapsule beads 4 prepared according to the same raw materials and preparation method as Example 3, except that the mass percentage of HDI / trihydroxymethyl hexyl lactone crosslinking polymer is replaced by 15%, the contents of other oil phase components are supplemented to 100% by equal ratio, and the rest of the phases remain unchanged.

[0059] Comparative Example 2 is a suspension of alcohol-in-oil microcapsule beads 5 prepared according to the same raw materials and preparation method as Example 3, except that the mass percentage of HDI / trihydroxymethyl hexyl lactone crosslinking polymer is replaced by 0.1%, the contents of other oil phase components are supplemented to 100% by equal ratio, and the rest of the phases remain unchanged.

[0060] Comparative Example 3 is a suspension of alcohol-in-oil microcapsule beads 6 prepared according to the same raw materials and preparation method as Example 3, except that the mass percentage of castor oil / IPDI copolymer is replaced by 35.2%, the contents of other oil phase components are supplemented to 100% by equal ratio, and the rest of the phases remain unchanged.

[0061] Comparative Example 4 is a suspension of alcohol-in-oil microcapsule beads 7 prepared according to the same raw materials and preparation method as Example 3, except that the mass percentage of castor oil / IPDI copolymer is replaced by 0.1%, the contents of other oil phase components are supplemented to 100% by equal ratio, and the rest of the phases remain unchanged.

[0062] Comparative Example 5 is a suspension of alcohol-in-oil microcapsule beads 8 prepared according to the same raw materials and preparation method as Example 3, except that the Acanthopanax giraldii extract is replaced by ascorbic acid, and the rest remains unchanged.

[0063] Comparative Example 6 is the same as Example 3 except that the Acanthopanax giraldii extract is replaced by retinol, and the rest is the same, finally obtaining an alcohol-in-oil microcapsule bead suspension 9;

[0064] Comparative Example 7 is the same as Example 3 except that the butanediol is replaced by deionized water, and the rest is the same, finally obtaining an alcohol-in-oil microcapsule bead suspension 10;

[0065] Comparative Example 8 is the same as Example 3 except that the Acanthopanax giraldii extract is removed, and the content of other alcohol phase components is supplemented by equal ratio to 100%, and the rest is the same, finally obtaining an alcohol-in-oil microcapsule bead suspension 11;

[0066] Comparative Example 9 is the same as Example 3 except that the flow focusing type microfluidic chip preparation alcohol-in-oil microcapsule bead process is replaced by a general stirring homogenization process, that is, the oil phase solution, the alcohol phase solution and the continuous phase solution are mixed together and stirred and homogenized to obtain an alcohol oil mixture.

[0067] The efficacy test scheme is as follows:

[0068] The alcohol-in-oil microcapsule bead suspensions 1-11 prepared by the above Examples 1-3 and Comparative Examples 1-8 are respectively filtered and dried to obtain dried alcohol-in-oil microcapsule beads 1-11, the alcohol oil mixture prepared by Comparative Example 9 is filtered and dried to obtain an oil emulsion; the above obtained alcohol-in-oil microcapsule beads 1-11 and oil emulsion are prepared into an essence as active substances to verify the efficacy. Essence 1 is prepared according to the formula shown in Table 2.

[0069] Table 2 Formula composition of essence 1

[0070]

[0071] Essences 2-12 are respectively obtained by replacing the alcohol-in-oil microcapsule beads 1 with alcohol-in-oil microcapsule beads 2-11 and the oil emulsion, and essence 13 is prepared by removing the alcohol-in-oil microcapsule beads 1 in the formula.

[0072] I. Stability test

[0073] The stabilities of essences 1-13 under the following test conditions are observed from the 1st day to the 12th week: light-shielded normal temperature test condition, light-shielded 45℃ test condition, light-shielded -10℃ test condition, light-shielded 5℃ test condition, 6500K light test condition, 45℃ and -10℃ high and low temperature cycle (i.e. after 24h of heat resistance at 45℃, it is placed at normal temperature for 12h, and then 24h of cold resistance at -10℃, and so on), and the results are shown in Tables 3-8.

[0074] Table 3 Stability under light-avoiding normal temperature test conditions

[0075]

[0076] Table 4 Stability under light-avoiding 45°C test conditions

[0077]

[0078] Table 5 Stability under light-avoiding -10°C test conditions

[0079]

[0080] Table 6 Stability under light-avoiding 5°C test conditions

[0081]

[0082] Table 7 Stability under light test conditions

[0083]

[0084] Table 8 Stability under light-avoiding cycle test conditions

[0085]

[0086] In view of the test results in Tables 3-8 above, in combination with the blank control group essence 13, the essences 1-3 are relatively stable under different test conditions, indicating that the structure of the alcohol-in-oil microcapsule beads prepared by the method of the present application has good stability, can effectively prevent the internal AMPELOPSIS GROSSEDENTATA extract components from directly contacting the external environment, reduce deterioration and discoloration due to oxidation, hydrolysis and other factors, and improve the stability of the active ingredients.

[0087] II. Skin feel test comparison

[0088] Through subject recruitment, 30 people with rich experience in skin feel evaluation were recruited to form an evaluation group. The members of the evaluation group were uniformly trained before the test to clearly define the standards and methods of skin feel evaluation, and to ensure the consistency and accuracy of the evaluation.

[0089] Test procedure: Under the same environmental conditions, the members of the evaluation group respectively took equal amounts (0.5 g) of samples and evenly applied them on the skin of the same area (about 5 cm x 5 cm) on the inner side of the arm. The following evaluation index system was followed to score in turn, and the evaluation results and subjective feeling descriptions were recorded. Each sample test interval was 1 hour to ensure that the skin condition returned to normal and avoid the influence of sample residues on subsequent tests.

[0090] Evaluation index and standard: develop skin feel evaluation index system, including smoothness of application (1-5 points, 1 point for extremely unsmooth, 5 points for extremely smooth), refreshing feeling (1-5 points, 1 point for sticky heavy, 5 points for comfortable and refreshing), stickiness (reverse scoring, 1 point for no stickiness, 5 points for severe stickiness), irritation (1-5 points, 1 point for low irritation, 5 points for high irritation).

[0091] Test results: the average value of different skin feel test data obtained by the members of the comprehensive evaluation group is calculated, as shown in Table 9.

[0092] Table 9 Skin feel test data

[0093]

[0094] As shown in Table 9, according to the evaluation group members' skin feel test data standard, combined with the comprehensive score of the smoothness, refreshing feeling and stickiness of the blank control group essence 13 and the essence 1-3, the skin feel is the best, and the irritation to human skin is the smallest. Therefore, it can be concluded that the alcohol-in-oil microcapsule beads prepared by the present application have good effects of improving skin feel and reducing irritation. The alcohol-in-oil microcapsule beads can isolate the ampelopsis japonica extract from the skin and reduce its direct irritation to the skin. At the same time, the alcohol phase can play a certain soothing effect, so that the product is more gentle to use and reduces the risk of allergy.

[0095] III. Comparison of antioxidant efficacy

[0096] The antioxidant capacity of the essence 1-13 was tested by selecting T / SHRH 006-2018 cosmetic-radical (DPPH) scavenging experiment method.

[0097] 1. Liquid preparation

[0098] (1) Positive control solution: dissolve and dilute vitamin E with 95% volume percentage ethanol into a series of gradient concentration solutions of 0.16 mg / mL, 0.08 mg / mL, 0.04 mg / mL, 0.02 mg / mL and 0.01 mg / mL to verify the test system.

[0099] (2) DPPH ethanol solution: weigh 12 mg of 1,1-diphenyl-2-trinitrobenzene hydrazine in a 250 mL beaker, add 100 mL of 95% volume percentage ethanol, and stir with a glass rod until dissolved to obtain a DPPH ethanol solution.

[0100] (3) Test sample solution: the essence 1-13 is used as the test object, which is diluted with water into a multi-level concentration sample. Five concentrations are set for each test object: 0.05%, 0.25%, 0.5%, 2.5% and 5.0% (all are mass percentage concentrations).

[0101] 2. Sample addition

[0102] Referring to Table 10, using 10 mL test tubes, sample tubes, sample background tubes, DPPH tubes and solvent background tubes are set up. For each concentration of each test substance, 3 parallel tubes are set up for the sample tubes and 3 parallel tubes are set up for the DPPH tubes.

[0103] First, 0.5 mL of the same concentration of sample solution or positive control solution is added to the sample tubes and sample background tubes. Then, solvent (water for water-soluble samples, 95% ethanol by volume for oil-soluble samples) is added to all the test tubes to make up 1.5 mL, and mixed. Then, 0.5 mL of DPPH ethanol solution is added to the sample tubes and DPPH tubes, and 0.5 mL of 95% ethanol by volume is added to the sample background tubes and solvent background tubes, and gently shaken and left to stand at room temperature for 5 minutes.

[0104] Table 10 Sample addition requirements

[0105]

[0106] 3. Detection

[0107] The sample-added test tubes are moved to a 96-well plate, and the absorbance is measured at 517 nm.

[0108] DPPH free radical scavenging rate calculation formula:

[0109] Scavenging rate (%) = [1 - (T - T0) / (C - C0)] x 100%

[0110] Wherein: T is the absorbance of the solution in the sample tube, i.e. the absorbance of the solution after the sample and DPPH react;

[0111] T0 is the absorbance of the solution in the sample background tube;

[0112] C is the average of the absorbance of the solution in the DPPH tube, i.e. the absorbance of the DPPH solution without the sample;

[0113] C0 is the absorbance of the solution in the solvent background tube.

[0114] 4. Detection results based on free radical (DPPH) scavenging experiments

[0115] The DPPH scavenging rate detection results of the sample group serum are shown in Table 11, and the DPPH scavenging rate detection results of the positive control group are shown in Table 12. The change trend of the DPPH scavenging rate of the serum is shown in Figure 2 , and the change trend of the DPPH scavenging rate of the positive control is shown in Figure 3 .

[0116] Table 11. DPPH radical scavenging rate of the serum

[0117]

[0118] Table 12. DPPH scavenging rate of the positive control group

[0119]

[0120] The positive control, vitamin E, has a good scavenging rate on DPPH radicals, and the concentration has a strong correlation and linearity with the scavenging rate, indicating that the designed test system is effective.

[0121] From Tables 11-12 and Figures 2-3As shown in the data, the DPPH radical scavenging rates of the oil-in-alcohol microcapsule beads obtained in Examples 1-3 are the highest at different dilution concentrations, which represents the strongest antioxidant capacity. In Comparative Examples 1 and 3, the microcapsule bead gel hardener component is excessive, and in combination with the special structure of the oil-in-alcohol microcapsule beads, the coating rate is low, the hardness is too high, and the active substance is not completely released. In Comparative Examples 2 and 4, the microcapsule bead gel hardener component is too low, and in combination with the special structure of the oil-in-alcohol microcapsule beads, the coating rate is low, the hardness is too soft, and the active substance is easily lost or oxidized, and the efficacy is greatly reduced. In Comparative Examples 5 and 6, the DPPH radical scavenging rate of the active ingredient wrapped in the microcapsule beads is lower than that of the active ingredient wrapped in the microcapsule beads in Examples, according to the test data measured at the same concentration of active ingredient. Ascorbic acid, retinol and butanediol have poor solubility, and are separated out, so their effect is not as good as that of Examples 1-3. In Comparative Example 7, deionized water is used instead of butanediol, but the alcohol-soluble extract of Ampelopsis aconitifolia is more than water-soluble, and the active ingredient is easily oxidized and lost, and the efficacy is far inferior to that of Examples 1-3. In Comparative Example 8, the active substance is removed, and the extract of Ampelopsis aconitifolia, i.e. dihydromyricetin (DHM), can eliminate ROS free radicals generated after UVA exposure, and ROS can further cause inflammatory reactions and cell apoptosis, so the extract of Ampelopsis aconitifolia has very good antioxidant efficacy, and the antioxidant efficacy of Comparative Example 8 is significantly reduced after the active substance of the extract of Ampelopsis aconitifolia is removed. In Comparative Example 9, the microcapsule bead production process is replaced, and the flow focusing microfluidic chip preparation process can produce microcapsule beads with high precision, uniform particle size and high coating rate, thereby stabilizing the content of the active ingredient wrapped in the microcapsule beads, and the prepared microcapsule beads have better antioxidant efficacy, while the antioxidant efficacy of the product obtained by using the ordinary stirring homogenization process in Comparative Example 9 is lower. From the above data, the antioxidant function of the oil-in-alcohol microcapsule beads of the present application is significantly effective, and in the actual addition amount of 2.5%-5.0%, it shows a dose-dependent effect, and the significant effect mainly depends on the raw material collocation, the special structure of the microcapsule beads and the microcapsule bead preparation technology.

[0122] Four, antioxidant efficacy comparison

[0123] The anti-glycation ability of the serum is tested by advanced glycation end product removal experiment for evaluating the efficacy in vitro. Non-enzymatic glycation of proteins changes the structure and function of proteins and other substances. The glycation of proteins in the human body is called advanced glycation end products (AGES). The continuous accumulation of AGES will make collagen fibers solidify, skin elasticity decrease, skin yellow and dull, and appear old. Most AGES are known to have fluorescence. The fluorescence values of the experimental group and the control group AGES are compared to calculate the inhibition rate of the active substance on AGES, thereby evaluating the anti-glycation effect of the raw material.

[0124] 1. Preparation of solution

[0125] (1) Positive control solution: 1,3-diaminoguanidine hydrochloride is diluted with pure water to obtain a series of gradient concentrations of 0.00005 mmol / mL, 0.00010 mmol / mL, 0.00020 mmol / mL, 0.00050 mmol / mL, and 0.00100 mmol / mL.

[0126] (2) Test sample solution: The serum 1-13 is used as the test substance, and is diluted with water to obtain samples of multiple concentrations. Five concentrations are set for each test substance: 0.5%, 1.0%, 2.5%, 5.0%, and 10.0% (all mass percentage concentrations).

[0127] 2. Sample addition

[0128] (1) The reaction system is prepared according to the amount of each reagent in Table 13, and mixed well. Three replicates are set for each concentration, and three background control wells are set.

[0129] Sample tube: The appropriate range of pipette is used to suck 1 mL of sample solution, slowly added to the corresponding labeled sample tube hole, try to avoid the generation of bubbles. Replace the new tip, suck 0.5 mL of bovine serum albumin solution, and add to the hole. Replace the tip again, suck 0.5 mL of glucose solution, and add to the same hole. Note that the tip should not touch the liquid level in the hole to avoid cross contamination, slowly release the liquid.

[0130] Sample blank tube: Use a pipette to suck 0.5 mL of bovine serum albumin solution and add to the hole labeled as a sample blank tube. Replace the tip, suck 1 mL of sample solution, and add to the same hole.

[0131] Positive control tube: Use a pipette to suck 1 mL of PBS1 buffer and add to the hole labeled as a positive control tube. Replace the tip, suck 0.5 mL of bovine serum albumin solution, and add to the hole. Replace the tip again, suck 0.5 mL of glucose solution, and add to the same hole.

[0132] The negative control blank tube: use a pipette to take PBS1 buffer and add it to the well labeled as the negative control blank tube, replace the pipette tip, take 0.5 mL of bovine serum albumin solution and add it to the well, replace the pipette tip again, take 0.5 mL of PBS2 buffer and add it to the same well. After 24 h of incubation at 37°C in the dark, detect the fluorescence intensity (excitation 360 nm, emission 460 nm) using a fluorescence spectrophotometer.

[0133] The buffer is a conventional PBS buffer; the buffer is prepared by replacing the oil-in-alcohol microcapsule beads 1 and deionized water in the formula of the essence 1 in Table 2 with a conventional PBS buffer. Two different PBS buffers are set up and specific groups are added, the purpose being to accurately exclude interference factors from different sources in the experimental system and ensure that the detection results only reflect the “cleavage effect of the essence on AGEs” and not the influence of other irrelevant variables (such as sample matrix, solvent, etc.).

[0134] Table 13: Reaction system for advanced glycation end product clearance rate test

[0135]

[0136] (2) Sample operation method: each sample was vortexed for 1 min to mix evenly, filtered through a 0.22 µm filter membrane and stored in a sterile centrifuge tube. After being placed in a 60°C oven for 40 h, 200 μL was taken and placed on a black enzyme-labeled plate, and fluorescence detection was performed at an excitation of 360 nm and an emission of 460 nm. The fluorescence absorbance value was recorded.

[0137] 3. The clearance rate of the sample on the advanced glycation end product was calculated according to the following clearance rate calculation formula:

[0138] Clearance rate (%) = [1 - (T - T0) / (C - NC0)] x 100%

[0139] In the formula: T is the absorbance value of the solution in the sample tube;

[0140] T0 is the absorbance value of the solution in the sample blank tube;

[0141] C is the absorbance value of the solution in the positive control tube;

[0142] NC0 is the absorbance value of the solution in the negative control blank tube.

[0143] 4. Detection results of the advanced glycation end product clearance experiment

[0144] The results of the advanced glycation end product clearance rate test of the sample group are shown in Table 15, the results of the advanced glycation end product clearance rate test of the positive control group are shown in Table 14, and the change trend of the advanced glycation end product clearance rate of the serum is shown in Figure 4 Figure 5

[0145] Table 14 1,3-diamino guanidine hydrochloride on advanced glycation end product clearance rate

[0146]

[0147] Table 15 Advanced glycation end product clearance rate test results data

[0148]

[0149] The positive control 1,3-diamino guanidine hydrochloride has good clearance rate on advanced glycation end product, and the concentration has strong correlation and linearity with the clearance rate, indicating that the designed test system is effective.

[0150] From Tables 14-15 and Figures 4-5 ​​As can be seen from the data, the product prepared in Examples 1-3 and Comparative Examples 1-9 has the highest removal rate of advanced glycation end products at different dilution concentrations, which represents the strongest anti-glycation ability. In Comparative Examples 1 and 3, the content of the microcapsule gel hardener is excessive, and combined with the special structure of the oil-in-alcohol microcapsule, it leads to low coating rate and high hardness, resulting in incomplete release of the active substances. In Comparative Examples 2 and 4, the content of the microcapsule gel hardener is too low, and combined with the special structure of the oil-in-alcohol microcapsule, it leads to low coating rate and soft hardness, resulting in easy loss or oxidation of the active substances, and a significant reduction in efficacy. In Comparative Examples 5 and 6, the efficacy of the active ingredient on the removal rate of advanced glycation end products is lower than that of the active ingredient in Examples, and the solubility of ascorbic acid and retinol in butanediol is poor, and there is precipitation, so the effect is not as good as that of Examples 1-3. In Comparative Example 7, butanediol is replaced by deionized water, but the alcohol solubility of Ampelopsis megalophylla extract is greater than the water solubility, and the active ingredient is easily oxidized and lost, and the efficacy is far inferior to that of Examples 1-3. In Comparative Example 8, the active substance is removed, and research shows that aldose reductase (AR) has many specific residues, such as THR-113 and LEU-300, and Ampelopsis megalophylla extract, as a flavonoid substance, can combine with the residues in the "specific pocket" of AR through hydrogen bond, van der Waals force, π-π conjugate bond, and carbon-hydrogen bond, thereby reducing the activity of AR and inhibiting the generation of AGES, and resisting aging, so Ampelopsis megalophylla extract has very good anti-glycation efficacy, and the anti-glycation efficacy of Comparative Example 8 is significantly reduced after the active substance Ampelopsis megalophylla extract is removed. In Comparative Example 9, the microcapsule production process is replaced, and compared with the ordinary stirring process, the former can produce microcapsules with high precision, uniform particle size and high coating rate, thereby stabilizing the content of the active ingredient, and the prepared microcapsules have better anti-glycation efficacy, while the anti-glycation efficacy of the product prepared by the ordinary stirring homogenization process in Comparative Example 9 is reduced. From the above data, it can also be seen that the serum 3 prepared by 10% of the oil-in-alcohol microcapsule 3 has a removal rate of 98.87% for advanced glycation end products, which indicates that the oil-in-alcohol microcapsule has an in vitro advanced glycation end product removal effect and a significant anti-glycation effect.

[0151] V. Anti-aging efficacy comparison

[0152] The inhibition of DNA methylation test method and the cytotoxicity test method were selected to test the applicable concentration and anti-aging ability of the serum.

[0153] 1. Cytotoxicity detection

[0154] Mitochondria of living cells contain succinate dehydrogenase, which can reduce exogenous thiazolyl blue to water-insoluble blue-violet crystalline formazan and deposit in the cells, while dead cells do not have this function. Dimethyl sulfoxide solution (DMSO) can dissolve formazan in the cells, and the absorbance value at 490 nm wavelength is measured by a multifunctional enzyme label instrument. Since the amount of crystallization is directly proportional to the number of living cells, the absorbance value can indirectly reflect the number of living cells.

[0155] (1) Preparation of solution

[0156] The essences 1-13 were used as test substances, and deionized water was used to dilute them into samples with multiple concentrations. For each test substance, five concentrations were set: 0.78125%, 1.5625%, 3.125%, 6.25%, and 12.5% (all mass percentage concentrations).

[0157] (2) Inoculation

[0158] Logarithmic growth phase cells were taken and inoculated into 96-well plates (5×10 5 cells / well) after digestion. The culture plates were placed in a 37°C, 5% CO2 incubator for incubation and culture for 24 h.

[0159] (3) Sample addition

[0160] The sample group was to add fresh culture medium containing the corresponding concentration of test substance sample to the cells, the normal control group was to add fresh culture medium to the cells, and the blank control group was blank culture medium; after sample addition was completed, incubation and culture were continued at 37°C in a 5% CO2 incubator for 24 h.

[0161] (4) Detection

[0162] After incubation, thiazolyl blue solution was added to each well, and incubation was continued for 4 h; the medium was removed, DMSO solution was added, and the absorbance value at 490 nm was measured after shaking and mixing.

[0163] The calculation formula of cell viability is as follows:

[0164] Cell viability (%) = [(OD sample group - OD blank control group) / (OD normal control group - OD blank control group)] × 100%

[0165] OD sample group is the absorbance value at 490 nm of the sample group;

[0166] OD blank control group is the absorbance value at 490 nm of the blank control group;

[0167] OD normal control group is the absorbance value at 490 nm of the normal control group.

[0168] (5) Results

[0169] The cell viability of different samples at different concentrations was detected. If p < 0.05 and the cell viability was less than 100%, it was determined that there was toxicity at this concentration. The detailed cell detection data results are shown in Table 16 and Figure 6 The cell viability (%, mean ± SD), p value and detection result determination are shown in Table 17. It can be found from the observation data that the cell viability of the serum sample group was greater than 100% at a mass percentage concentration of 0.78125%, which revealed that the sample had no cytotoxicity at a mass percentage concentration of 0.78125%.

[0170] Table 16 Cell toxicity detection data

[0171]

[0172] Table 17 p value and detection result determination

[0173]

[0174] 2. DNA methylation inhibition test

[0175] DNA methylation is an important epigenetic modification that plays a key role in regulating gene expression and cellular function. With age, the DNA methylation pattern in skin cells changes, which is closely related to abnormal gene expression and decreased cellular function, ultimately leading to the characteristics of skin aging. Therefore, exploring small molecule compounds that can adjust these methylation patterns may provide a new way to delay the aging process. DNA methyltransferase 1 (DNMT1) is a key enzyme that is responsible for transferring methylation marks from the original DNA strand to the newly synthesized DNA strand during DNA replication during cell division, thereby maintaining the epigenetic memory of cells. Some studies have found that moderately inhibiting the activity of DNMT1 may help restore the original methylation state of cells, thereby promoting cell regeneration and repair, and thus resisting aging. Therefore, in this test, an experimental model of human immortalized keratinocytes was established, and the relative expression of DNMTI gene was detected after the sample was applied to the cells, to evaluate whether the sample had the effect of inhibiting DNA methylation.

[0176] (1) Liquid preparation

[0177] Based on the conclusions of the above cytotoxicity test, and assuming that the sample is not cytotoxic at a mass percentage concentration of 0.78125%, the sample was further diluted to different concentrations, and the concentration was further subdivided. Essence 1-13 was used as the test substance and diluted with deionized water to obtain samples of multiple concentrations. Each test substance was set with 3 concentrations: 0.390625%, 0.78125%, and 1.5625% (all mass percentages).

[0178] (2) Vaccination

[0179] Logarithmic growth phase cells were harvested, digested, and seeded into 6-well plates (6 × 10⁶ cells / well). 5 (number of cells / well), place the culture plate at 37°C, 5% [presumably a specific concentration]. Incubate in an incubator for 24 hours.

[0180] (3) Samples

[0181] After incubation, remove the culture medium and wash with D-Hanks solution 1-2 times. The sample group received fresh culture medium containing the corresponding concentration of the test substance, the normal control group received fresh culture medium, and the blank control group received blank culture medium. After sample administration, continue incubation at 37°C with 5%... Incubate in an incubator for 24 hours.

[0182] (4) Extract total RNA from each experimental group, synthesize cDNA, and use q-PCR to detect β-acrin and the target gene.

[0183] (5) Using β-acrin as an internal reference for gene expression, calculate the relative RNA expression level of the target gene.

[0184] Equation (1)

[0185] Equation (2) ΔC(t) = ΔC(t) Normal control group Sample group

[0186] Equation (3) ∆C(t) = C(t) target gene −

[0187] Equation (1) is the core formula for calculating the relative expression level of the target gene in q-PCR (real-time quantitative PCR) experiments. This formula is used to calculate the fold relationship between the expression level of the target gene (such as DNA methyltransferase gene DNMT1) in the sample group and the normal control group, directly reflecting the regulatory effect (inhibition or promotion) of the target gene expression by the sample.

[0188] In formula (2), AC(t) normal control group: C(t) value of the normal control group (no sample intervention, normal cell growth) (i.e. Ct difference of DNMT1 and β-actin of the normal control group); AC(t) sample group: C(t) value of the sample group (addition of the sample to be tested) (Ct difference of DNMT1 and β-actin of the sample group); ΔΔC(t)>0 indicates that the expression amount of DNMT1 of the sample group is lower than that of the normal control group (the sample inhibits the expression of DNMT1); ΔΔC(t)<0 indicates that the expression amount of the sample group is higher (the sample promotes the expression of DNMT1).

[0189] In formula (3), C(t) target gene: cycle threshold value of the DNMT1 gene (cycle number when PCR amplification reaches the set fluorescence intensity, which is negatively correlated with the initial concentration of the gene); C(t) β-actin: cycle threshold value of the internal reference gene (β-actin, stably expressed housekeeping gene).

[0190] (6) Detect the relative expression amount of DNMT1 gene and p value under different sample concentrations. If statistical analysis p<0.05, it is determined that there is a significant difference. The relative expression amount of DNMT1 gene detection data results are shown in Tables 18 and Figure 7 The p value and detection result determination are shown in Table 19. From Tables 18-19 and Figure 7As can be seen from the data, the relative expression of DNMT1 gene of the oil-in-alcohol microcapsule beads prepared in Examples 1-3 is the lowest at different dilution concentrations, which represents the strongest anti-aging effect; the microcapsule bead gel hardener component in Comparative Examples 1 and 3 is excessive, combined with the special structure of the oil-in-alcohol microcapsule beads, resulting in low coating rate and high hardness, which causes incomplete release of the active substances; the microcapsule bead gel hardener component in Comparative Examples 2 and 4 is too low, combined with the special structure of the oil-in-alcohol microcapsule beads, resulting in low coating rate and soft hardness, which causes easy loss or oxidation of the active substances, and a significant reduction in efficacy; the relative expression of DNMT1 gene of the active ingredient in Comparative Examples 5 and 6 is higher than that of the active ingredient in Examples at the same concentration, among which ascorbic acid, retinol and butanediol have poor compatibility, and are separated out, so the DNA methylation inhibition effect is not as good as Ampelopsis aconitifolia extract; in Comparative Example 7, deionized water is used to replace butanediol, but the alcohol solubility of Ampelopsis aconitifolia extract is greater than the water solubility, and the active ingredient is easily oxidized and lost, and the effect is far inferior to Examples 1-3; in Comparative Example 8, the active substance is removed, and according to the test data, the relative expression of DNMT1 gene of Ampelopsis aconitifolia extract is significantly reduced compared with the control group, and has a significant inhibition effect on DNA methylation, so Ampelopsis aconitifolia extract has very good anti-aging effect, and the anti-aging effect of Comparative Example 8 is significantly reduced after the active substance Ampelopsis aconitifolia extract is removed; in Comparative Example 9, the microcapsule bead production process is replaced, and the flow focusing microfluidic chip technology process can produce microcapsule beads with high precision, uniform particle size and high coating rate, so that the content of the active ingredient is stable, and the anti-aging effect of the prepared microcapsule beads is better, while the anti-aging effect of the product obtained by using the ordinary stirring homogenization process in Comparative Example 9 is reduced. Therefore, it can be found from the observation data that the relative expression of DNMT1 gene of the sample group 3 is significantly reduced compared with the normal control group, which indicates that the sample has a significant inhibition effect on DNA methylation, that is, the anti-aging effect is significantly improved with the increase of the concentration under the premise of ensuring no cytotoxicity.

[0191] Table 18 DNMT1 gene relative expression detection result data

[0192]

[0193] Table 19 p value and detection result determination

[0194]

[0195] In summary, the alcohol-in-oil microcapsule beads have significant effects on antioxidation, anti-glycation and anti-aging.

[0196] The above embodiments are preferred embodiments of the present application, but the embodiments of the present application are not limited to the above embodiments, and any changes, modifications, substitutions, combinations, simplifications, etc. made without departing from the spirit and principles of the present application should be equivalent replacement manners and should be included in the protection scope of the present application.

Claims

1. A method for preparing oil-in-alcohol microcapsules, characterized in that... Follow these steps: (1) Selecting oil phase solution, alcohol phase solution and continuous phase solution: The oil phase solution is composed of the following components by mass percentage: HDI / trimethylolhexyl lactone crosspolymer 4.8~10%, castor oil / IPDI copolymer 14~22%, squalane 40~50%, meadowfoam seed oil 10~20%, diisostearyl malate 10~12%, ascorbic acid tetraisopalmitate 0.1~0.5%, tocopherol 1~5% and ceramide NP 0.1~0.5%; The alcohol phase solution is composed of the following components by mass percentage: Ampelopsis japonica extract 20~40% and butanediol 60~80%; The continuous phase solution is composed of the following components by mass percentage: stabilizer 0.1~0.5% and pure water 99.5~99.9%, wherein the stabilizer is carbomer or xanthan gum; The mass percentages of the oil phase solution, alcohol phase solution and continuous phase solution are 40%, 20% and 40%, respectively; (2) Preparation of alcohol-in-oil microcapsules using flow-focusing microfluidic chips: The alcohol phase solution is injected from one end of the main channel near the oil phase channel, and then the oil phase solution is injected from both ends of the oil phase channel. At the intersection of the oil phase channel and the main channel, the alcohol phase solution is squeezed and dispersed into droplets by the oil phase solutions on both sides. The oil phase solution containing droplets continues to flow forward, while the continuous phase solution is injected from both ends of the outer phase channel. The oil phase solution containing droplets mixes with the continuous phase solution to form a suspension of alcohol-in-oil microcapsules. They flow out from the outlet of the main channel, are cooled and allowed to stand for further solidification, and a stable suspension of alcohol-in-oil microcapsules is obtained.

2. The method for preparing an oil-in-alcohol type microcapsule according to claim 1, characterized in that: The flow-focusing microfluidic chip in step (2) is provided with a main channel, an oil phase channel and an outer phase channel. The oil phase channel and the outer phase channel are arranged sequentially along the conveying direction of the main channel. The extension directions of the oil phase channel and the outer phase channel are perpendicular to the extension direction of the main channel and are respectively connected to the main channel.

3. The method for preparing an oil-in-alcohol microcapsule according to claim 1, characterized in that: In step (2), the flow rate ratio of the alcohol phase solution and the oil phase solution is controlled at 1:4-1:8 to ensure that the particle size range of the oil-in-alcohol microcapsules is controlled within 0.5-1mm.

4. The method for preparing an oil-in-alcohol microcapsule according to claim 1, characterized in that: The stable suspension of oil-in-alcohol microcapsules obtained in step (2) is further post-processed, including filtration and drying.

5. An oil-in-alcohol type microcapsule prepared by the preparation method according to any one of claims 1 to 4.

6. The use of the oil-in-alcohol microcapsule according to claim 5 in the preparation of cosmetics with antioxidant, anti-glycation and anti-aging effects.

Images